Shane Kovacs

2017 - PTC Therapeutics

In 2017, Shane Kovacs earned a total compensation of $707.7K as Former Executive Vice President, Chief Financial Officer and Head of Corporate Development at PTC Therapeutics, a 67% decrease compared to previous year.

Compensation breakdown

Option Awards$406,010
Salary$189,436
Stock Awards$101,070
Other$11,206
Total$707,722

Kovacs received $406K in option awards, accounting for 57% of the total pay in 2017.

Kovacs also received $189.4K in salary, $101.1K in stock awards and $11.2K in other compensation.

Rankings

In 2017, Shane Kovacs' compensation ranked 10,565th out of 14,666 executives tracked by ExecPay. In other words, Kovacs earned more than 28.0% of executives.

ClassificationRankingPercentile
All
10,565
out of 14,666
28th
Division
Manufacturing
4,109
out of 5,772
29th
Major group
Chemicals And Allied Products
1,464
out of 2,075
29th
Industry group
Drugs
1,195
out of 1,731
31st
Industry
Pharmaceutical Preparations
929
out of 1,333
30th
Source: SEC filing on April 30, 2018.

Kovacs' colleagues

We found six more compensation records of executives who worked with Shane Kovacs at PTC Therapeutics in 2017.

2017

Stuart Peltz

PTC Therapeutics

Chief Executive Officer

2017

Marcio Souza

PTC Therapeutics

Chief Operating Officer

2017

Mark Boulding

PTC Therapeutics

Chief Legal Officer

2017

Mark Rothera

PTC Therapeutics

Former Chief Commercial Officer

2017

Neil Almstead

PTC Therapeutics

Executive Vice President, Research, Pharmaceutical Operations & Technology

2017

Christine Utter

PTC Therapeutics

Principal Financial Officer and Treasurer

News

In-depth

You may also like